• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    6/11/26 8:32:06 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    xray-20260611
    0000818479false00008184792026-06-112026-06-11

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K
    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    June 11, 2026
    Date of Report (Date of earliest event reported)

    DENTSPLY SIRONA Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    0-16211
    39-1434669
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
    13320 Ballantyne Corporate Place,
    Charlotte
    North Carolina
    28277-3607
    (Address of principal executive offices)
    (Zip Code)
    (844) 848-0137
    (Registrant’s telephone number, including area code)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.01 per shareXRAYThe Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    o



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    On June 1, 2026, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed John C. Fortson as the Company’s Executive Vice President & Chief Financial Officer, effective as of July 20, 2026 (the “Effective Date”).

    Mr. Fortson, age 58, currently serves as the President and Chief Financial Officer of Kymera International (“Kymera”), a global manufacturer of advanced performance materials and surface technologies. He has served as Chief Financial Officer, since March 2025, and began serving as President in April 2026. Prior to joining Kymera, Mr. Fortson served from 2020 to 2024 as President & Chief Executive Officer and as a member of the board of directors of Ingevity Corporation (“Ingevity”), a company that creates products and technologies including those relating to automotive gasoline vapor emissions control systems, food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, and paint for road markings. Mr. Fortson also served as Chief Financial Officer of Ingevity from 2015 to 2020. Mr. Fortson received his Bachelor of Science degree from the United States Military Academy at West Point and his Master of Business Administration degree from Duke University’s Fuqua School of Business.

    The Company and Mr. Fortson have executed an offer letter pursuant to which Mr. Fortson will serve as the Company’s Executive Vice President & Chief Financial Officer (the “Offer Letter”). Pursuant to the Offer Letter, Mr. Fortson will be paid an annual base salary of $780,000 and will be eligible for a target annual bonus of 85% of base salary (which target amount will be prorated for 2026).

    Also pursuant to the Offer Letter, beginning in 2027, Mr. Fortson will be eligible to receive an annual equity award with a target grant date fair value of $2,500,000 in a mix of equity vehicles consistent with awards approved for other members of the Company’s management committee as approved annually by the Compensation & Human Capital Committee of the Board.

    In addition, pursuant to the Offer Letter, Mr. Fortson will receive a sign-on cash payment in the amount of $500,000 payable in the Company’s first pay period in February 2027, which amount must be repaid to the Company within 45 days of termination if Mr. Fortson’s employment ceases within 12 months of the Effective Date for any reason other than involuntary, not for cause termination. Mr. Fortson will also be eligible to receive a sign-on equity award with a target grant date fair value of $700,000, to be granted on the second trading day after the start of his employment or, if such date is not within an open trading window under the Company’s Insider Trading Policy, on the second trading day after the filing of the Company’s next Quarterly Report on Form 10-Q. The sign-on equity award will be 60% in the form of premium stock options and 40% in the form of restricted stock units, each with three-year ratable vesting.

    The Offer Letter also provides that Mr. Fortson will be provided certain employee benefits, including, among other things, paid time off, health and welfare benefits, eligibility to participate in the Company’s Supplemental Savings Plan and the Company’s Supplemental Executive Retirement Plan, and relocation benefits. Mr. Fortson’s employment is also subject to the Company’s Amended and Restated Key Employee Severance Benefits Plan and the Company’s Key Employee Change of Control Severance Benefits Plan.

    Mr. Fortson has also entered into a Confidentiality and Non-Competition Agreement with the Company, which contains customary provisions including, for example, that Mr. Fortson will not accept employment with a competitor for two years from the date upon which his employment with the Company terminates, subject to certain exceptions.

    Mr. Fortson does not have any family relationship with any director or executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    The foregoing summary of Mr. Fortson’s Offer Letter is qualified in its entirety by reference to the text of the Offer Letter, which is furnished as Exhibit 10.1 hereto.

    Item 7.01 Regulation FD Disclosure

    The Company’s press release announcing the appointment of Mr. Fortson as the Company’s Executive Vice President & Chief Financial Officer is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.




    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

    Exhibit No.Description
    10.1
    Offer Letter between DENTSPLY SIRONA Inc. and John C. Fortson, entered into as of May 30, 2026
    99.1
    DENTSPLY SIRONA Inc. Press Release Issued June 11, 2026
    104Cover Page Interactive Data File (embedded within the Inline XBRL Document)





    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             DENTSPLY SIRONA Inc.

    By:/s/ Daniel T. Scavilla
    Daniel T. Scavilla
    President and Chief Executive Officer

    Date: June 11, 2026

    Get the next $XRAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2026$10.00Sell
    Citigroup
    2/19/2026$17.00Neutral → Buy
    BofA Securities
    12/9/2025$12.00Underweight
    Barclays
    11/7/2025Outperform → Mkt Perform
    William Blair
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    More analyst ratings

    $XRAY
    SEC Filings

    View All

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    6/11/26 8:32:06 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    6/4/26 4:23:44 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DENTSPLY SIRONA Inc.

    SD - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    6/1/26 6:01:20 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dentsply Sirona Appoints John Fortson as Chief Financial Officer

    CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of John Fortson as Executive Vice President (EVP) and Chief Financial Officer (CFO), effective July 20. Mr. Fortson joins Dentsply Sirona with more than 25 years of leadership experience in finance, operations, and strategy across both public and private equity-backed companies. He has served for 13 years as either CFO or Chief Executive Officer of global manufacturing and industrial businesses. Throughout his career, he has executed large-sc

    6/11/26 8:30:00 AM ET
    $NGVT
    $XRAY
    Major Chemicals
    Industrials
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Continues to Expand U.S. Distribution Network to Strengthen Access to its Digital Dentistry Solutions Across Key Regional Markets

    CHARLOTTE, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the strengthening of its U.S. distribution footprint through an expanded partnership with Nashville Dental, Inc (NDI), a leading independent dental distributor serving the Southeast and Mid-Atlantic regions. As of August 1, 2026, NDI's portfolio will include Dentsply Sirona's full range of connected technology solutions, including the CEREC system, Primescan intraoral scanners, and digital imaging solutions. This expansion allows dental practices across a nine-state territory to access the company's

    5/26/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference

    CHARLOTTE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the 2026 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 27, 2026, at 3:35 p.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to

    5/20/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on Dentsply Sirona with a new price target

    Citigroup initiated coverage of Dentsply Sirona with a rating of Sell and set a new price target of $10.00

    4/15/26 8:07:52 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00

    2/19/26 7:47:02 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Dentsply Sirona with a new price target

    Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00

    12/9/25 8:44:01 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Amendment: Director Mazelsky Jonathan Jay bought $101,400 worth of shares (10,000 units at $10.14), increasing direct ownership by 19% to 61,669 units (SEC Form 4)

    4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/18/26 6:23:46 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Hosein Clyde bought $64,902 worth of shares (6,500 units at $9.98), increasing direct ownership by 10% to 70,575 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/16/26 5:03:34 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Mckeon Brian P bought $101,200 worth of shares (10,000 units at $10.12) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/15/26 5:06:36 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Mazelsky Jonathan Jay bought $101,400 worth of shares (10,000 units at $10.14), increasing direct ownership by 19% to 61,669 units (SEC Form 4)

    4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/18/26 6:23:46 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    New insider Barton-Brobst Lindi Rene claimed ownership of 45,440 shares (SEC Form 3)

    3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/18/26 4:23:43 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Hosein Clyde bought $64,902 worth of shares (6,500 units at $9.98), increasing direct ownership by 10% to 70,575 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    6/16/26 5:03:34 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints John Fortson as Chief Financial Officer

    CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of John Fortson as Executive Vice President (EVP) and Chief Financial Officer (CFO), effective July 20. Mr. Fortson joins Dentsply Sirona with more than 25 years of leadership experience in finance, operations, and strategy across both public and private equity-backed companies. He has served for 13 years as either CFO or Chief Executive Officer of global manufacturing and industrial businesses. Throughout his career, he has executed large-sc

    6/11/26 8:30:00 AM ET
    $NGVT
    $XRAY
    Major Chemicals
    Industrials
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Reports First Quarter 2026 Results

    News Summary Reported net sales of $880 millionDelivered GAAP gross margin of 48.5%, GAAP net loss per share of ($0.05)Achieved adjusted gross margin of 50.7%, adjusted EBITDA margin of 14.7%, adjusted EPS of $0.27Launched Smart View-Detect, the world's first FDA-cleared, AI-enabled diagnostic aid designed to identify teeth with periapical radiolucencies (PARL) in CBCT scans, now also CE-marked for use across EuropeContinued to penetrate connected technology solutions market with new Atlanta Dental Supply distributor agreementInstalled first CEREC® system under the new Benco Dental distribution agreement, marking an important early milestoneBegan implementing new capital allocation strategy

    5/5/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5

    CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to review its first quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast link and call information will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the c

    4/22/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/12/24 4:23:31 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care